5月8日,罗氏制药中国宣布投资20.4亿元,用于在上海新建生物制药生产基地。本次投资用于法瑞西单抗注射液的本地化生产 ,不断满足中国患者对于创新疗法需求。公司预计:该项目2029年正式落成,2031年正式投产。这个投资项目位于张江高科技园区,建筑面积约2.5万平方米,是罗氏制药在中国的第二个创新药物生产基地。待建成之后,将与百米之外的罗氏制药中国区总部现有生产基地协同运作。同样在5月8日,阿斯利康...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.